Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Vildan Kayku Liv Hospital Bahçeşehir Spec. MD. Vildan Kayku Medical Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
7 Essential Facts About ADT Drugs for Prostate Cancer Treatment
7 Essential Facts About ADT Drugs for Prostate Cancer Treatment 2

When facing prostate cancer, knowing about androgen deprivation therapy is key. At Liv Hospital, we focus on safe and effective treatments. We make sure our care is based on solid evidence and tailored to each patient.

Androgen deprivation therapy is a mainstay for treating advanced prostate cancer. It works by lowering male hormone levels, which slows cancer cell growth. We’ll share important facts about these drugs, showing their role and benefits in prostate cancer treatment.

Key Takeaways

  • Androgen deprivation therapy is a key treatment for advanced prostate cancer.
  • Lowering male hormone levels helps slow cancer cell growth.
  • Liv Hospital offers evidence-based care and patient-focused protocols.
  • Safe and effective treatments are available for prostate cancer management.
  • Understanding treatment options is vital for patients facing prostate cancer.

Understanding Prostate Cancer and Hormone Dependency

prostate cancer hormone dependency
7 Essential Facts About ADT Drugs for Prostate Cancer Treatment 3

It’s key to know how hormones and prostate cancer are linked for good treatment. Prostate cancer grows because of hormones, like testosterone. We’ll see how these hormones help cancer grow and when we need hormone therapy.

The Role of Testosterone in Prostate Cancer Growth

Testosterone is a hormone that helps prostate cells grow. In prostate cancer, it makes cancer cells grow faster. High testosterone levels can make hormone-dependent prostate cancer cells grow more, which is why it’s so important.

  • Testosterone promotes the growth of prostate cancer cells.
  • Androgen deprivation therapy (ADT) aims to reduce testosterone levels.
  • Lowering testosterone levels can slow down or stop the growth of prostate cancer.

When Hormone Therapy Becomes Necessary in Treatment

Hormone therapy, or ADT, is needed when prostate cancer is advanced or has spread. ADT is a treatment that lowers male hormones, like testosterone, which help prostate cancer cells grow. By reducing testosterone, ADT can slow the disease’s growth.

We decide if hormone therapy is needed based on the cancer’s stage and grade, and the patient’s health. Knowing when to start hormone therapy is key for managing prostate cancer well.

What is ADT? Defining Androgen Deprivation Therapy

androgen deprivation therapy
7 Essential Facts About ADT Drugs for Prostate Cancer Treatment 4

Androgen Deprivation Therapy (ADT) is a key treatment for prostate cancer. It’s used for advanced or hormone-sensitive cases. ADT lowers male hormones, or androgens, which prostate cancer cells need to grow.

The Science Behind Testosterone Suppression

ADT works by reducing testosterone levels. This slows down or stops prostate cancer cell growth. Medications block testosterone production or its action on cancer cells. The goal is to deprive prostate cancer cells of the hormones they need to grow.

Historical Development of ADT for Prostate Cancer

The idea of ADT started in the 1940s. It was noticed that prostate cancer could regress with castration or estrogen therapy. Now, ADT has evolved with LHRH agonists and antagonists. These can achieve chemical castration without surgery.

Statistics on ADT Usage in Prostate Cancer Patients

ADT is a common treatment for prostate cancer. Studies show many prostate cancer patients get ADT. About 50% of cases use ADT, showing its key role in fighting the disease.

Common ADT Drugs Used in Prostate Cancer Management

Androgen Deprivation Therapy (ADT) is key in fighting prostate cancer. It uses different drugs to lower testosterone levels. These drugs help slow down tumor growth. Let’s look at the types of ADT drugs and their roles in treating prostate cancer.

LHRH Agonists: Leuprolide (Lupron), Goserelin (Zoladex)

LHRH agonists first raise testosterone levels but then lower them. Leuprolide (Lupron) and Goserelin (Zoladex) are examples. They are given by injection, usually monthly or every few months.

LHRH Antagonists: Degarelix (Firmagon)

Degarelix (Firmagon) blocks LHRH directly, lowering testosterone right away. It’s good for those who might have problems with the initial testosterone rise from LHRH agonists.

Anti-Androgens: Bicalutamide (Casodex), Flutamide

Anti-androgens block testosterone from reaching androgen receptors. Bicalutamide (Casodex) and Flutamide are examples. They’re often used with LHRH drugs to block androgens more effectively.

First-Generation vs. Second-Generation Anti-Androgens

First-generation anti-androgens like Flutamide are mostly replaced by second-generation ones. Second-generation anti-androgens, like Enzalutamide (Xtandi), block androgens better and are used for advanced cancer.

Choosing the right ADT drug depends on many things. These include the cancer stage, patient health, and possible side effects. Doctors and patients work together to find the best treatment plan.

ADT Drug Administration: Injection Methods and Schedules

ADT drugs can be given through injections or pills, each with its own benefits. The choice depends on the drug type, patient preference, and treatment plan.

Understanding 1-Month, 3-Month, and 6-Month Formulations

LHRH agonists, like leuprolide and goserelin, are often given as injections. These come in 1-month, 3-month, and 6-month forms. How often you get an injection depends on the type and your treatment plan.

FormulationInjection FrequencyExamples
1-MonthEvery 1 monthLeuprolide (Lupron)
3-MonthEvery 3 monthsGoserelin (Zoladex)
6-MonthEvery 6 monthsLeuprolide (Eligard)

The Injection Process and What Patients Can Expect

The injection is usually given in the office. It might hurt a bit, but the pain is short-lived.

Oral ADT Options and Their Administration

Anti-androgens, like bicalutamide and flutamide, are taken by mouth. You might need to take them once or twice a day. Always follow the dosage and schedule your doctor gives you.

Managing ADT treatment can be tough. Our healthcare team is here to help and support you every step of the way.

Treatment Protocols: Continuous vs. Intermittent ADT

Androgen Deprivation Therapy (ADT) is key in treating advanced prostate cancer. There are two main ways to do this: continuous and intermittent therapy. The choice depends on the patient’s health, cancer stage, and treatment side effects.

Benefits and Drawbacks of Continuous Therapy

Continuous ADT means always taking ADT drugs without stopping. The main plus is it keeps testosterone levels low, helping to slow cancer growth. But, it can cause side effects like hot flashes, tiredness, and less sex drive. It might also raise the risk of long-term problems like bone loss and heart disease.

Intermittent ADT: Reducing Side Effects While Maintaining Efficacy

Intermittent ADT, by contrast, has treatment cycles followed by breaks. It tries to lessen side effects while keeping cancer under control. Research shows it can make life better by cutting down on side effect time. Yet, how well it works can vary, and it’s important to watch closely when to start treatment again.

How Doctors Determine the Optimal Protocol for Each Patient

Doctors look at many things when picking between continuous and intermittent ADT. They consider the cancer’s stage and how aggressive it is, the patient’s health, and how they react to ADT first. They make treatment plans that work best for each person, aiming to be effective while avoiding too many side effects. It’s key to keep checking in and adjust the plan as needed.

Advanced Combination Therapies with ADT

Advanced combination therapies with Androgen Deprivation Therapy (ADT) have changed how we treat prostate cancer. By mixing ADT with other treatments, doctors can give patients better care.

ADT with Abiraterone (Zytiga): Enhanced Androgen Blockade

One big step forward is using ADT with abiraterone (Zytiga). Abiraterone blocks the enzyme CYP17, which makes testosterone. This makes the androgen blockade stronger. Research shows this combo can help patients live longer and slow down cancer growth.

ADT with Enzalutamide (Xtandi): Targeting Androgen Receptors

Another great combo is ADT with enzalutamide (Xtandi). It targets androgen receptors directly. Enzalutamide blocks androgens from binding to the androgen receptor. This stops tumor growth. Studies have shown this combo greatly improves outcomes for advanced prostate cancer patients.

ADT Combined with Radiation or Chemotherapy

ADT is also paired with radiation or chemotherapy for better results. Recent studies have shown that ADT-based combos are now standard for metastatic castration-sensitive prostate cancer. The timing of these treatments is key to success.

Timing Considerations for Multimodal Treatment

When mixing ADT with other treatments, timing is everything. Doctors must choose the right time to start treatments. This ensures the best results and fewer side effects.

Managing the Side Effects of ADT Drugs

Androgen Deprivation Therapy (ADT) is a key treatment for prostate cancer. But, it has side effects that need careful handling. It’s important to know how to lessen these effects.

Physical Changes: Hot Flashes, Fatigue, and Body Composition

ADT can cause big changes in the body. These include hot flashes, feeling tired, and changes in body shape. Hot flashes can be very uncomfortable and disrupt daily life. Fatigue makes it hard to have energy and feel well.

Sexual Function and Libido Impacts

Sexual problems and lower libido are big worries for ADT patients. These issues can affect a patient’s life in many ways, not just physically.

Cardiovascular and Metabolic Risks

ADT can raise the risk of heart and metabolic problems. It’s key to watch and manage these risks to avoid serious issues later on.

Bone Health and Fracture Prevention

ADT can make bones weaker, leading to osteoporosis and fractures. Keeping bones healthy is very important for patients on this therapy.

Cognitive and Emotional Effects

ADT can also cause changes in thinking and mood swings. It’s important to deal with these effects to keep patients’ quality of life good.

Understanding and managing ADT side effects helps healthcare providers give better care. This improves the life of prostate cancer patients.

Strategies to Minimize ADT Treatment Side Effects

Patients with prostate cancer on ADT may face various side effects. But, with the right strategies, these can be managed well. It’s key to improve their life quality during treatment.

Exercise and Nutrition During ADT Therapy

Exercise and nutrition are key in reducing ADT side effects. Regular workouts help with weight, bones, and energy. Eating well, with lots of fruits, veggies, and whole grains, also helps manage weight and health.

  • Aerobic exercises like walking or cycling can improve cardiovascular health.
  • Resistance training can help maintain muscle mass and bone density.
  • A diet low in saturated fats and high in fiber can help manage weight and improve metabolic health.

Medications and Treatments for Symptom Relief

Many medications and treatments can ease ADT side effects. For example, bisphosphonates prevent bone loss, and some antidepressants help with hot flashes.

“Managing the side effects of ADT requires a multifaceted approach that includes lifestyle changes, medications, and regular monitoring.”

-Dr. Oncologist

The Importance of Regular Monitoring and Follow-up

Regular check-ups and follow-ups are vital for managing ADT side effects. Doctors can adjust treatments based on how patients react and their side effects.

Support Groups and Psychological Resources

Support groups and psychological resources offer emotional support. They help patients deal with ADT’s mental impact. These resources are very helpful in improving outcomes and life quality.

By using these strategies, patients on ADT can manage their side effects better. This improves their overall well-being.

Patient Selection: Who Benefits Most from ADT Therapy?

The success of ADT in treating prostate cancer depends on choosing the right patients. Androgen Deprivation Therapy (ADT) has changed how we manage prostate cancer, mainly for advanced cases. It’s also used in other stages, requiring careful thought to see who benefits most.

ADT for Advanced and Metastatic Prostate Cancer

For those with advanced or metastatic prostate cancer, ADT is key. It lowers testosterone, slowing cancer growth. Research shows ADT greatly helps these patients, improving their life and survival chances.

ADT in Combination with Radiation for Localized Disease

In localized prostate cancer, ADT is often paired with radiation. This combo is great for high-risk patients. Together, ADT and radiation can better control the cancer and lower recurrence risk.

Risk-Benefit Assessment for Different Patient Profiles

Choosing ADT for prostate cancer patients needs a detailed look at risks and benefits. Age, health, and other conditions are key in deciding if ADT is right.

Age and Comorbidity Considerations

Older or patients with serious health issues need a tailored ADT approach. ADT’s side effects, like bone and heart risks, must be weighed against its benefits. A personalized plan can improve results and reduce side effects.

Deciding on ADT should involve a full review of the patient’s health and preferences. By carefully choosing who gets ADT, doctors can enhance its benefits and reduce risks.

Liv Hospital’s Innovative Approach to ADT Administration

At Liv Hospital, we’re changing how Androgen Deprivation Therapy (ADT) is given to prostate cancer patients. We aim to give top-notch healthcare by always looking for new ways to improve treatments.

Cutting-Edge Protocols and Personalized Treatment Plans

We use the newest ADT methods to make treatment plans that fit each patient’s needs. Our cutting-edge protocols help patients get the best care they can.

Multidisciplinary Care Team Approach

Our team of experts works together to give full care. This multidisciplinary approach makes sure all parts of a patient’s health are looked at during treatment.

Patient Support Services During ADT Treatment

ADT can be tough to go through. That’s why we have a range of patient support services. They help with the physical and emotional sides of treatment.

International Standards and Treatment Outcomes

At Liv Hospital, we follow international standards in our treatments. This means our patients get care that’s among the best worldwide. Our focus on being the best shows in our treatment results.

Conclusion: The Evolving Landscape of ADT in Prostate Cancer Care

Androgen Deprivation Therapy (ADT) is key in fighting prostate cancer. The way we use ADT is changing with new treatments and drugs.

ADT drugs, like LHRH agonists and antagonists, lower testosterone levels. This slows down cancer growth. Adding drugs like abiraterone and enzalutamide makes treatments even better.

The future of ADT in prostate cancer care is bright. Research is ongoing to make treatments better and reduce side effects. At Liv Hospital, we use the latest ADT advancements to help our patients.

We are committed to giving our patients the best care. This means using new treatments and working together as a team. Our goal is to make sure our patients get the best care possible.

What is Androgen Deprivation Therapy (ADT) and how does it work?

ADT is a treatment for prostate cancer. It lowers male hormone levels to slow cancer cell growth. It does this by reducing testosterone production or blocking its effects.

What are the common ADT drugs used for prostate cancer management?

Common ADT drugs include LHRH agonists like leuprolide (Lupron) and goserelin (Zoladex). There are also LHRH antagonists like degarelix (Firmagon) and anti-androgens like bicalutamide (Casodex) and flutamide.

How are ADT drugs administered?

ADT drugs can be given as injections or pills. The method depends on the drug and treatment plan.

What are the side effects of ADT treatment?

Side effects may include hot flashes, fatigue, and changes in body composition. They can also affect sexual function and libido. There are risks to the heart, metabolism, and bones.

Can ADT be used in combination with other treatments?

Yes, ADT can be used with other treatments like radiation or chemotherapy. This can make it more effective against prostate cancer.

What is the difference between continuous and intermittent ADT?

Continuous ADT is ongoing treatment. Intermittent ADT stops and starts treatment to reduce side effects. The choice depends on the patient’s needs and doctor’s advice.

How can the side effects of ADT be managed?

Managing side effects includes exercise, nutrition, and medications. Regular monitoring and follow-up care are also important. Support groups and psychological resources can help too.

Who is a good candidate for ADT therapy?

Patients with advanced or metastatic prostate cancer may benefit from ADT. Those with localized disease treated with ADT and radiation might also benefit. The decision is based on a risk-benefit assessment.

What is Liv Hospital’s approach to ADT administration?

Liv Hospital offers a personalized approach to ADT. They have a multidisciplinary care team and patient support services. This ensures complete care during treatment.

Are there new developments in ADT treatment?

Yes, ADT treatment is evolving. New developments and emerging trends include advanced combination therapies and innovative protocols.

References

  • National Cancer Institute (NCI): https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet
  • OncoLink: https://www.oncolink.org/cancers/prostate/treatments/taking-androgen-deprivation-therapy-adt-for-prostate-cancer
  • American Cancer Society (ACS): https://www.cancer.org/cancer/types/prostate-cancer/treating/hormone-therapy.html
  • National Center for Biotechnology Information (NCBI) / PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC8702790/

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Get a Free Quote

Response within 2 hours during business hours

Clinics/branches
GDPR

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Vildan Kayku Liv Hospital Bahçeşehir Spec. MD. Vildan Kayku Medical Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
Trusted Worldwide
30
Years of
Experience
30 Years Badge
Health Türkiye Accreditation

Trusted Worldwide

30 Years of Experience

Patient Reviews
Reviews from 9,651
4,9
Was this content helpful?
Your feedback helps us improve.
What did you like?
Share more details about your experience.
You must give consent to continue.

Thank you!

Your feedback has been submitted successfully. Your input is valuable in helping us improve.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Vildan Kayku Medical Oncology

Spec. MD. Vildan Kayku

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 28 17